Amyloidosis trials in Spain
25 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleMAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Where
- A Coruña, Barcelona, L'hospitalet De Llobregat, Madrid, Málaga, Palma, Pamplona, Salamanca
- Age
- 18 years to 90 years
- People
- 1,200 worldwide
- Run by
- Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00 - No phaseTaking peopleMulticenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
- Where
- Huelva, Palma de Mallorca, San Sebastián
- Age
- 18 years and over
- People
- 2,200 worldwide
- Run by
- Idoven 1903 S.L.
See details and how to joinNCT06978660 - Phase 1Taking peopleA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- Badalona, Barcelona, Madrid, Pamplona, Salamanca
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00 - Phase 2Taking peopleA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
- Where
- Barcelona, Gijón, Málaga, Pamplona, Salamanca
- Age
- 18 years to 64 years
- People
- 60 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07224672 · EU 2025-522803-60-00 - No phaseTaking peoplePrevalence of Amyloidosis in Trauma Patients
- Where
- Sant Pere de Ribes
- People
- 246
- Run by
- Consorci Sanitari de l'Alt Penedès i Garraf
See details and how to joinNCT06527521 - Phase 3Enrolling by invitationA Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Málaga
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT06679946 - Phase 3Taking peopleCLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- Where
- A Coruña, Badalona, Barcelona, Bilbao, Córdoba, Donostia / San Sebastian, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Palma de Mallorca, Santiago de Compostela, Seville, Úbeda, Valencia, Zaragoza
- Age
- 18 years and over
- People
- 1,280 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07207811 - Phase 3Taking peopleTRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- A Coruna, Barcelona, Bilbao, Huelva, Jaén, L'hospitalet De Llobregat, Lleida, Madrid, Majadahonda, Murcia, Palma, Pamplona, Salamanca, Santiago De Compostela, Valencia, Vigo
- Age
- 18 years to 85 years
- People
- 1,750 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00 - No phaseTaking peopleConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
- Where
- Barcelona, Madrid, Palma
- People
- 1,500 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT04561518 - No phaseTaking peoplePatisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
- Where
- Madrid
- People
- 10 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT05040373 - Phase 3Taking peopleTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Where
- Barcelona, Huelva, L'hospitalet De Llobregat, Madrid, Palma
- Age
- 18 years to 85 years
- People
- 125 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00 - No phaseTaking peopleA Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
- Where
- Multiple Locations
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- Bayer
See details and how to joinNCT07235462 - Phase 1Taking peopleA Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
- Where
- Barcelona, Salamanca
- Age
- 18 years and over
- People
- 276 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06768489 · EU 2024-515316-44-00 - No phaseTaking peopleNon-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- Where
- Barcelona, Bilbao, Cataluna, Huelva, Islas Baleares, Las Palmas de Gran Canaria, Majadahonda, Salamanca
- Age
- 18 years to 130 years
- People
- 1,850 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06465810 - No phaseTaking peopleLong-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
- Where
- Majadahonda
- Age
- 18 years and over
- People
- 320 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07654855 - No phaseTaking peopleOverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- Where
- A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Las Palmas de Gran Canaria, Madrid, Majadahonda, Palma de Mallorca, Salamanca, Valencia
- People
- 52,121 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06355934 - Phase 3Not yet taking people in SpainAn Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
- Where
- A Coruña, Barcelona, El Palmar, Jaén, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Palma de Mallorca, Pamplona, Salamanca, Santiago de Compostela-Coru A, Valencia
- People
- 1,180 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00 - No phaseTaking peopleRetinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
- Where
- L'Hospitalet de Llobregat, Madrid, Palma de Mallorca
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07690436 - Phase 1/2Taking peopleA Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Where
- Barcelona, Gijón, Madrid, Móstoles, Murcia, Palma, Pamplona, Valencia
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06292780 · EU 2023-507809-34-00 - Phase 3Not yet taking people in SpainTo Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
- Where
- A Coruña, Huelva, L'hospitalet De Llobregat, Majadahonda, Palma, Salamanca
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473 · EU 2024-513676-18-00 - Phase 3Taking peopleAcoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Where
- A Coruna, Huelva, L'hospitalet De Llobregat, Majadahonda, Palma, Salamanca
- Age
- 18 years to 75 years
- People
- 587 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00 - Phase 4Taking peopleCardiac Magnetic Resonance and Echocardiography Study With Acoramidis
- Where
- Huelva, L'hospitalet De Llobregat, Majadahonda, Palma, Salamanca
- Age
- 18 years to 80 years
- People
- 150 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07695701 · EU 2026-526068-19-00 - Phase 3Enrolling by invitationAn Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
- Where
- Barcelona, Majadahonda, Murcia, Santiago de Compostela
- Age
- 18 years and over
- People
- 1,400 worldwide
- Run by
- Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493 - No phaseTaking peopleA EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
- Where
- Pamplona
- Age
- 18 years to 99 years
- People
- 400 worldwide
- Run by
- Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT06205953 - Phase 3Not yet taking people in SpainEffect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction
- Where
- A Coruña, Barcelona, Ciudad Real, Donostia, L'hospitalet De Llobregat, Majadahonda, Salamanca, Santiago de Compostela, Zaragoza
- Age
- 18 years and over
- People
- 114
- Run by
- Puerta de Hierro University Hospital
See details and how to joinNCT06712030 · EU 2024-515661-34-00